Correction

Correction: Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway

Mathieu Chocry[1], Ludovic Leloup[1] and Hervé Kovacic[1]

[1] Aix-Marseille Université, INSERM, CRO2 UMR_S 911, Marseille 13385, France

Published: *June 01, 2018*

This article has been corrected: The correct figures are given below:
The authors declare that these corrections do not change the results or conclusions of this paper.



Figure 2: Implication of Nox1 in oxaliplatin-induced ROS production and cytotoxicity. (D). Transfected cells were also seeded in white 96-well plates to perform lucigenin assays.



Figure 3: Study of calpain expression, activity and implication in oxaliplatin-induced cytotoxicity. (C). The transfected cells were also seeded to perform 72-hour cytotoxicity assays **(C)**. Asteriks indicate a statistical significance with $p<0.05$.



Figure 7: Implication of p38 in the resistance to oxaliplatin. (B to D). Cytotoxicity assays were performed with HT29-D4, Rox1 and Rox2 treated with oxaliplatin and incubated in the absence (Control) or in the presence of SB203580, a specific inhibitor of p38 (5 μM) **.**

Original article: Oncotarget. 2017; 8:103710-103730. https://doi.org/10.18632/oncotarget.21780